ライフサイエンスコーパス: C. trachomatis

1 C. trachomatis and T. vaginalis infection increase the s

2 C. trachomatis assembles its membrane systems from the u

3 C. trachomatis has adjacent genes encoding the separate

4 C. trachomatis multiplies exclusively inside host cells

5 C. trachomatis samples were typed using multilocus seque

6 C. trachomatis strains can be differentiated by sequenci

7 C. trachomatis was detected at follow-up in 39 subjects

8 C. trachomatis was detected from 59 rectal swabs and 8 p

9 se seen with T. vaginalis (9.0%; P = 0.005), C. trachomatis (6.2%), and N. gonorrhoeae (1.4%).

10 (adjusted odds ratio [AOR], 1.75; P = .103), C. trachomatis (AOR, 1.43; P = .247), and T. vaginalis (

11 e, 37/45 C. trachomatis-positive and 197/212 C. trachomatis-negative samples were detected (sensitivi

12 The 25 C. trachomatis specimens with PCR-positive results (obta

13 1-7.1]), HSV-2 excretion (26.7 [2.9-244.3]), C. trachomatis (11.7 [2.3-58.9]), and M. genitalium infe

14 hom 52 tested C. trachomatis positive and 41 C. trachomatis negative.

15 Using the plasmid-based assay alone, 37/45 C. trachomatis-positive and 197/212 C. trachomatis-negat

16 reated HLA-DR4 transgenic mice with 5 x 10(5)C. trachomatis D inclusion forming units (IFU) induced a

17 Although a C. trachomatis cteG mutant did not display a defect in i

18 c manipulation have allowed us to generate a C. trachomatis strain expressing a heterologous CD4(+) T

19 e genetics to evaluate the contribution of a C. trachomatis gene to disease pathogenesis.

20 Here, we determined the ability of a C. trachomatis recombinant major outer membrane protein

21 Replacing C. muridarum pgp5 with a C. trachomatis pgp5 still inhibited the plasmid-dependen

22 Additionally, C. trachomatis replication depends on a subset of altere

23 ection frequently occurs within months after C. trachomatis infection treatment.

24 or CD4(+) T cell-mediated protection against C. trachomatis infection in the genital mucosa.

25 idate CtFabI as a therapeutic target against C. trachomatis.

26 5% confidence interval [CI], 9.5%-24.0%) and C. trachomatis prevalence was 14.7% (95% CI, 7.8%-21.6%)

27 (odds ratio [OR] 0.85, 95% CI 0.75-0.95) and C. trachomatis infection (OR 0.67, 95% CI 0.55-0.78).

28 Human C. pneumoniae (Cpn) and C. trachomatis (Ctr) seroreactivity was 54% biased towar

29 tion testing would detect N. gonorrhoeae and C. trachomatis (or T. vaginalis if utilized), there is n

30 greement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational assays compared to

31 greement for detection of N. gonorrhoeae and C. trachomatis for three investigational assays compared

32 oth pharyngeal and rectal N. gonorrhoeae and C. trachomatis.

33 1% in the pharynx and 7.9% in the rectum and C. trachomatis positivity of 2.0% in the pharynx and 8.7

34 using a novel cis complementation approach, C. trachomatis lacking tarP demonstrated significant att

35 ia species associated with human disease are C. trachomatis, which is the leading cause of both repor

36 DNA for whole-genome sequencing; however, as C. trachomatis is an obligate intracellular pathogen, th

37 mido thiazolino 2-pyridones which attenuated C. trachomatis infectivity without affecting host cell o

38 tes of the proportion of PID cases caused by C. trachomatis are 35% (95% credible interval [CrI], 11%

39 D, but the proportion of PID cases caused by C. trachomatis is unclear.

40 um is probably longer than for NGU caused by C. trachomatis.

41 s in mammalian cells, themselves hijacked by C. trachomatis to sustain their own metabolic needs.

42 ng subversion of cellular innate immunity by C. trachomatis.

43 he NOD2-dependent activation of NF-kappaB by C. trachomatis-infected cell lysates as a biomarker for

44 utamate reduced in vivo synthesis of mDAP by C. trachomatis to undetectable levels, thus confirming t

45 hospholipid molecular species synthesized by C. trachomatis contained oleic acid, an abundant host fa

46 included 98 women who were contact-traced by C. trachomatis-positive sex partners at the STI outpatie

47 Upon entry into host cells, C. trachomatis resides within a membrane-bound compartme

48 can be challenging, as mice naturally clear C. trachomatis when it is deposited in the lower genital

49 by comparison to a 6-month audit of clinical C. trachomatis TMA (12,999 specimens) on the basis of th

50 provides another target for agents to combat C. trachomatis infection.

51 tool to aid public health efforts to control C. trachomatis and N. gonorrhoeae infections.

52 mpt to elucidate the mechanism that controls C. trachomatis adaptability.

53 For decades C. trachomatis has been considered an "energy parasite"

54 o exert their effector function and decrease C. trachomatis burden.

55 Cepheid Xpert CT/NG assay (Xpert) to detect C. trachomatis and N. gonorrhoeae in rectal and pharynge

56 than that of SOC testing (96%) for detecting C. trachomatis (P = 0.167).

57 eatment were new infections with a different C. trachomatis strain rather than reinfection with the s

58 thology, and infertility caused by different C. trachomatis serovars.

59 orted more often in subjects with discordant C. trachomatis strains than in those with concordant str

60 Half of the subjects with discordant C. trachomatis strains who reported sexual activity sinc

61 277 samples from 260 MSM identified distinct C. trachomatis strains circulating concurrently over tim

62 This study investigates whether distinct C. trachomatis strains circulate among subpopulations wi

63 -/-), and IL-4Ralpha(-/-) mice with low-dose C. trachomatis inoculums.

64 days, respectively) in two studies: (i) dry C. trachomatis-seeded swabs were used with ACT after sto

65 e report that levels of CXCL10 change during C. trachomatis infection of cultured cells in a manner d

66 poor memory CD8(+) T cell development during C. trachomatis infection of mice.

67 g different urine samples spiked with either C. trachomatis or N. gonorrhoeae, and also containing bo

68 , reported recent sexual contact with either C. trachomatis or N. gonorrhoeae, or had symptoms of an

69 ores the CD8(+) T cell response and enhances C. trachomatis clearance.

70 the fecal-oral route; (2) in the modern era, C. trachomatis causes "opportunistic" infection at non-G

71 ion and for the Tarp effector as a bona fide C. trachomatis virulence factor.

72 Finally, C. trachomatis infection interferes with the SNX5:CI-MPR

73 Here, we identified CteG as the first C. trachomatis effector associated with the Golgi.

74 survivin levels was also detected following C. trachomatis infection, which was reversed by blocking

75 For C. trachomatis, neither system was >95% sensitive from t

76 For C. trachomatis, Xpert was 95% sensitive (95% CI, 86 to 9

77 [95% confidence interval {CI}, .20-1.23] for C. trachomatis infection, 0.56 [95% CI, .19-1.67] for N.

78 ed with 2.1% for N. gonorrhoeae and 1.6% for C. trachomatis.

79 ween the two conditions tested were >98% for C. trachomatis and 100% for N. gonorrhoeae.

80 a, and conjunctival swabs were collected for C. trachomatis detection and to analyze the expression o

81 fferent chemokine receptors are critical for C. trachomatis-specific CD4(+) T cells to home to the lu

82 nstrate that FASII activity is essential for C. trachomatis proliferation within its eukaryotic host

83 The enrollment visit OmpA genotypes for C. trachomatis were determined for 162 subjects (92% fem

84 n used to predict up to 59 putative Incs for C. trachomatis; however, localization to the inclusion m

85 ion of 300 colony forming units (CFU)/mL for C. trachomatis and 1500CFU/mL for N. gonorrhoeae.

86 three sources from 148 and 154 patients for C. trachomatis and N. gonorrhoeae, respectively.

87 p in 9 of 11 (82%) participants positive for C. trachomatis and 7 of 10 (70%) participants positive f

88 The positivity rate for C. trachomatis was highest for rectal (16.2%), followed

89 with highest diagnostic yield is rectum for C. trachomatis and rectum and oropharynx for N. gonorrho

90 polymerase chain reaction [PCR] results for C. trachomatis DNA by Roche Amplicor) and 25 true-negati

91 two methods did not differ significantly for C. trachomatis (P = 0.774) or N. gonorrhoeae (P = 0.163)

92 esulted in collection of 2,408 specimens for C. trachomatis, N. gonorrhoeae, and T. vaginalis TMA scr

93 f a true "gold standard" diagnostic test for C. trachomatis.

94 y analyzed data from 655 patients tested for C. trachomatis (887 specimens) and N. gonorrhoeae (890 s

95 Participants were tested for C. trachomatis and N. gonorrhoeae at three sites (anorec

96 Specimens were tested for C. trachomatis and N. gonorrhoeae using a Gen-Probe Apti

97 and transport medium (n = 5) were tested for C. trachomatis rRNA by NAAT.

98 Subjects were enrolled, tested for C. trachomatis, treated with azithromycin, and scheduled

99 predictive values of 3 diagnostic tests for C. trachomatis infection.

100 e the development of specific treatments for C. trachomatis.

101 Plasmid-free C. trachomatis is also attenuated in both the mouse geni

102 Plasmid-free C. trachomatis serovar L2 organisms can be transformed w

103 econd HLA-B27-restricted T-cell epitope from C. trachomatis with relevance in ReA demonstrated to be

104 scherichia coli was toxic to cells, LOS from C. trachomatis did not induce any appreciable cell death

105 periplasmic domain of the RsbU protein from C. trachomatis (PDB 6MAB) displays close structural simi

106 ia pseudotuberculosis and also secreted from C. trachomatis in infected cells where it localizes appr

107 ating the potential role of gastrointestinal C. trachomatis in human chlamydial pathogenesis.

108 Genital C. trachomatis strains can counter tryptophan limitation

109 s-mucosa protective immunity against genital C. trachomatis infection following intranasal immunizati

110 ositive predictive values for M. genitalium, C. trachomatis, N. gonorrhoeae, and T. vaginalis were 10

111 With a reduced genome, C. trachomatis is dependent on its host for survival, in

112 er, relatively little is known regarding how C. trachomatis is able to hijack host cell metabolism.

113 However, C. trachomatis can productively infect mice when the low

114 transgenic mouse model for evaluating human C. trachomatis vaccine antigens are discussed.

115 ice, which replicates many features of human C. trachomatis infection and avoids the characteristic l

116 Importantly, C. trachomatis and C. pneumoniae are Trp auxotrophs and

117 (tri-diaminopimelic acid) in E. coli and in C. trachomatis These findings suggest that Chlamydia evo

118 this, Incs fused to APEX2 were expressed in C. trachomatis L2.

119 By tagging proteins expressed in C. trachomatis with OVA(323-339), we can begin to unders

120 evelopmentally controlled ompA expression in C. trachomatis.

121 s the complete deletion of specific genes in C. trachomatis L2.

122 expressing a FLAG-tagged version of IncD in C. trachomatis.

123 e data point to an AasC-dependent pathway in C. trachomatis that selectively scavenges host saturated

124 of the trpRBA tryptophan salvage pathway in C. trachomatis.

125 vidence of circulating genomic resistance in C. trachomatis.

126 , a major suppressor of metabolite supply in C. trachomatis-infected cells.

127 evidence for the significant role of Tarp in C. trachomatis invasion of host cells.

128 evelopments in the genetic transformation in C. trachomatis, we constructed a versatile green fluores

129 onality of the chlamydial Opp transporter in C. trachomatis Importantly, we found that one chlamydial

130 C. trachomatis detection after treatment in C. trachomatis-infected subjects seen at a sexually tran

131 to demonstrate DapF (Ct) function in vivo in C. trachomatis We reasoned that, because DapF (Ct) utili

132 ne-bound intracellular niche, the inclusion, C. trachomatis relies on a set of effector proteins that

133 ignificantly reduced IFN-gamma and increased C. trachomatis burden in the endometrial tissue, confirm

134 pGP3 deficiency also significantly increased C. trachomatis susceptibility to lactic acid.

135 Therefore, probenecid may inhibit C. trachomatis growth by an as yet unresolved mechanism.

136 tty acids were incorporated exclusively into C. trachomatis-produced phospholipid molecular species.

137 s added to the medium were incorporated into C. trachomatis-derived phospholipid molecular species.

138 that interact with Chlamydia, we introduced C. trachomatis into mouse endometrium via transcervical

139 uridarum, a model pathogen for investigating C. trachomatis pathogenesis, readily spreads from the mo

140 alpinx in mice and is used for investigating C. trachomatis pathogenicity.

141 The exploitation of genetically labeled C. trachomatis organisms with P3-driven GFP allows for t

142 Live C. trachomatis recovered from vaginal swabs or endometri

143 basis of bioinformatic analysis of multiple C. trachomatis genomes, led us to re-evaluate the previo

144 hus, we screened a population of mutagenized C. trachomatis strains for mutants that failed to reacti

145 Plasmid copy number, C. trachomatis load and disease severity were assessed i

146 search and clinical use in diagnosing ocular C. trachomatis infections.

147 report the whole-genome sequences of ocular C. trachomatis isolates obtained from young children wit

148 rethra/cervix) testing identified 92-100% of C. trachomatis or N. gonorrhoeae infections in participa

149 The burden of C. trachomatis and N. gonorrhoeae infection was signific

150 imilar large sample of data on the burden of C. trachomatis and N. gonorrhoeae infections by anatomic

151 P3 region verifies that P3 is a new class of C. trachomatis sigma(66)-dependent promoter, which requi

152 or innate immunity in endometrial control of C. trachomatis infection.

153 Culture of C. trachomatis has, until now, been a prerequisite to ob

154 Ms support the full infectious life cycle of C. trachomatis in a manner that mimics the infection of

155 N in situ at the late developmental cycle of C. trachomatis.

156 l specimens resulted in greater detection of C. trachomatis (6.1% and 11.3% rates, respectively) than

157 critical for the comprehensive detection of C. trachomatis and N. gonorrhoeae in the pediatric popul

158 identity factors may influence detection of C. trachomatis and N. gonorrhoeae infections at specific

159 ays for ultrafast and sensitive detection of C. trachomatis DNA from vaginal swabs.

160 he sensitivity of Cobas for the detection of C. trachomatis in female specimens was 95.6% (95% confid

161 city estimates of Cobas for the detection of C. trachomatis in male urine samples were 100% (96.8% to

162 The detection of C. trachomatis in ocular specimens by NAAT was verified

163 egradation in the AC2 assay for detection of C. trachomatis or N. gonorrhoeae was observed, although

164 Probe Aptima Combo 2 assay) for detection of C. trachomatis ribosomal RNA (rRNA) from direct ocular s

165 The specificity for the detection of C. trachomatis was >=98.8% for all female sample types.

166 ehaviors impact the anatomic distribution of C. trachomatis and N. gonorrhoeae infection is needed to

167 fection prevented the first cell division of C. trachomatis, although the cell morphology suggested d

168 ic review to investigate the epidemiology of C. trachomatis organism load in human genital chlamydia

169 ays a significant role in the eradication of C. trachomatis during the infection of macrophages.

170 ative PCR analysis showed that expression of C. trachomatis glycolytic enzymes inversely correlated w

171 esent in serum, rapidly induce expression of C. trachomatis tryptophan synthase, even under condition

172 oyl-acyl carrier protein reductase (FabI) of C. trachomatis to determine whether chlamydial FASII is

173 progress has been hindered by the failure of C. trachomatis to induce clinically relevant pathology i

174 A common feature of C. trachomatis persistence models is that reticulate bod

175 our study displayed the clinical features of C. trachomatis and N. gonorrhoeae, the 2 organisms that

176 study the development-dependent function of C. trachomatis promoters in an attempt to elucidate the

177 uter membrane protein A (OmpA) genotyping of C. trachomatis strains.

178 e activity of DapF compromises the growth of C. trachomatis Thus, a substrate competition strategy ca

179 t several analogues can impair the growth of C. trachomatis without affecting host cell viability.

180 ld be protected by vaccination, 10(4) IFU of C. trachomatis D was delivered intranasally, and mice we

181 rvically 6 weeks later with 5 x 10(5) IFU of C. trachomatis D.

182 lls were infected with a clinical isolate of C. trachomatis, and inclusions containing chlamydial dev

183 mid-free lymphogranuloma venereum isolate of C. trachomatis, serovar L2, with either the original shu

184 The infectious load of C. trachomatis before MDA was determined in 30 children

185 d as few as 10 inclusion-forming units/ml of C. trachomatis in less than 9 min, including DNA extract

186 rs were also associated with reduced odds of C. trachomatis infection: lack of ocular discharge (OR 0

187 derivatives de-repress the trpRBA operon of C. trachomatis strains with trpA or trpB mutations, no a

188 We assessed the positivity of C. trachomatis and N. gonorrhoeae infections at differen

189 with men, have shown that the prevalence of C. trachomatis and N. gonorrhoeae infections is much hig

190 contributing to the increased prevalence of C. trachomatis in the human GI tract.

191 ting, the estimated population prevalence of C. trachomatis ocular infection was approximately 17.5%.

192 drial fragmentation prevented replication of C. trachomatis even in p53-deficient cells.

193 tives function by acting as de-repressors of C. trachomatis TrpR.

194 have been associated with increased risk of C. trachomatis infection, suggesting that the impact of

195 This study demonstrates the role of C. trachomatis and number of recent sexual partners in t

196 Biochemical analysis established the role of C. trachomatis-encoded acyltransferases in producing the

197 tion of Cdu1 led to increased sensitivity of C. trachomatis for IFNgamma and impaired infection in mi

198 ting infectivity across multiple serovars of C. trachomatis without host cell toxicity.

199 Due to the genetically intractable status of C. trachomatis at that time, this model of IncD-CERT int

200 The 1.58A crystal structure of C. trachomatis hypothetical protein CT263 presented here

201 ed that the putative OppABCDF transporter of C. trachomatis functions in both oligopeptide transport

202 AFN-1252 treatment of C. trachomatis-infected HeLa cells at any point in the i

203 ous findings and to advance understanding of C. trachomatis genetic expression.

204 NAs (miRNAs) in maintaining the viability of C. trachomatis-infected primary human cells.

205 d avoids the characteristic low virulence of C. trachomatis in the mouse, we previously demonstrated

206 conducted whole-genome sequence analysis on C. trachomatis isolates collected from a previously desc

207 Current data on C. trachomatis phylogeny show that there is only a singl

208 OmpA genotyping was performed on C. trachomatis-positive urogenital specimens obtained fr

209 ts with monoinfections with M. genitalium or C. trachomatis compared to women with no detectable STIs

210 to be significantly associated with TF/TI or C. trachomatis infection, and the use of sanitation faci

211 transmission of Chlamydia closely parallels C. trachomatis sexual transmission in humans and may be

212 Currently, a vaccine to prevent C. trachomatis infections is not available.

213 Primary C. trachomatis infection of mice also causes no genital

214 strated a critical role of CPAF in promoting C. trachomatis survival in the mouse lower genital tract

215 Professional phagocytes provide C. trachomatis only a limited ability to survive and are

216 Using pure C. trachomatis, the MAMEF assays detected as few as 10 i

217 ng of Inc function(s), we subjected putative C. trachomatis Incs to affinity purification-mass spectr

218 ormatics analysis suggests that the putative C. trachomatis oligopeptide transporter OppABCDF (OppABC

219 For the qualitative RealTime C. trachomatis/N. gonorrhoeae assay, the overall agreeme

220 f anal intercourse, were screened for rectal C. trachomatis using the Gen-Probe Aptima COMBO 2 Assay.

221 revalence and factors associated with rectal C. trachomatis among female sexually transmitted infecti

222 scheduled for a 6-month follow-up for repeat C. trachomatis testing.

223 Our study demonstrates that most repeat C. trachomatis detections after treatment were new infec

224 ng to investigate the epidemiology of repeat C. trachomatis detection after treatment in C. trachomat

225 tool in understanding the origins of repeat C. trachomatis detection after treatment.

226 er in those with versus those without repeat C. trachomatis detection.

227 In this review, we revisit C. trachomatis pathogenesis data from mice and humans us

228 ere we present the structure of the secreted C. trachomatis protein Pgp3, an immunodominant antigen a

229 Incidence of any bacterial STI (C. trachomatis, N. gonorrhoeae, or M. genitalium infecti

230 fection, a model that has been used to study C. trachomatis pathogenesis in women, is known to depend

231 nse, is unable to protect against subsequent C. trachomatis infections.

232 t within a few days, while a CPAF-sufficient C. trachomatis strain (L2-5) survived in the lower genit

233 Although several lines of evidence suggest C. trachomatis utilizes host phospholipids, the bacteriu

234 haracterized for 93 women, of whom 52 tested C. trachomatis positive and 41 C. trachomatis negative.

235 eless, C. muridarum Pgp5 is more potent than C. trachomatis Pgp5 in suppressing gene expression.

236 tions were significantly more prevalent than C. trachomatis and N. gonorrhoeae infections, while the

237 In this study, we demonstrate that C. trachomatis infection of the upper genital tract resu

238 Our results indicate that C. trachomatis profoundly remodels the host proteome ind

239 Our results indicate that C. trachomatis utilizes functionally diverse genes to me

240 ogether with the intriguing observation that C. trachomatis CopN does not bind tubulin, our data supp

241 Genomic analysis predicts that C. trachomatis is capable of type II fatty acid synthesi

242 We now report that C. trachomatis Pgp3 can neutralize the antichlamydial ac

243 ry, this experimental approach revealed that C. trachomatis broadly alters host proteins and can be a

244 We show that C. trachomatis require mitochondrial ATP for normal deve

245 In this work, we are showing that C. trachomatis has an active respiratory metabolism that

246 The genomic data suggest that C. trachomatis respiratory chain could produce a sodium

247 ation with bacterial burden, suggesting that C. trachomatis actively suppresses CXCL10.

248 The C. trachomatis FabI (CtFabI) is a homotetramer and exhib

249 The C. trachomatis polymorphic membrane protein D (PmpD) is

250 s lactate dehydrogenase, are enriched at the C. trachomatis inclusion membrane during infection.

251 s TMA (12,999 specimens) on the basis of the C. trachomatis detection rate, specimen source distribut

252 We previously proposed that insertion of the C. trachomatis effector protein IncD into the inclusion

253 a presented here show that expression of the C. trachomatis effector protein IncD mediates the recrui

254 nstead being placed within UGT clades of the C. trachomatis phylogenetic tree.

255 ars; P < 0.0001) and higher than that of the C. trachomatis-infected females (mean, 23.8 years; P = 0

256 For appropriate therapy, C. trachomatis conjunctivitis should be diagnosed defini

257 For this, C. trachomatis strains expressing candidate effectors fu

258 from each child and tested for antibodies to C. trachomatis.

259 rtion of reproductive damage attributable to C. trachomatis Further studies using modern assays in co

260 amma) resistance of C. muridarum compared to C. trachomatis in the murine genital tract.

261 The PEFs of PID due to C. trachomatis decline steeply with age by a factor of a

262 lation excess fractions (PEFs) of PID due to C. trachomatis, using routine data, surveys, case-contro

263 tion of chlamydia might have been exposed to C. trachomatis but not infected.

264 of excess l-glutamate or meso-DAP (mDAP) to C. trachomatis resulted in 90% reduction in bacterial ti

265 roach to other host cytokines in response to C. trachomatis and found evidence that RANTES, another T

266 elected by evolution as the host response to C. trachomatis in the human female genital tract to cont

267 terize the mucosal CD8(+) T cell response to C. trachomatis in the murine genital tract.

268 In response to C. trachomatis infection, IL23A and PDGF were significan

269 onses were associated with susceptibility to C. trachomatis, whereas cytokines involved in Th1 polari

270 for successful CD4(+) T cell trafficking to C. trachomatis-infected tissues, we will be better equip

271 and young adults for Chlamydia trachomatis (C. trachomatis) and Neisseria gonorrhoeae (N. gonorrhoea

272 genital infection by Chlamydia trachomatis (C. trachomatis) is a major cause.

273 ice were more susceptible to a transcervical C. trachomatis D infection than WT mice.

274 eotide transporters, the ATP/ADP translocase C. trachomatis Npt1 (Npt1(Ct)) and the nucleotide unipor

275 dometrial resistance to sexually transmitted C. trachomatis infection in women.

276 Wild-type C. trachomatis entry into HeLa cells resulted in host ce

277 nflammation- and caspase-inducing, wild-type C. trachomatis serovar L2 led to infertility, but the no

278 isolates appear to be recombinants with UGT C. trachomatis genome backbones, in which loci that enco

279 uridarum, a murine model of human urogenital C. trachomatis, with severely attenuated disease develop

280 igens that can be applied to humans, we used C. trachomatis serovar D (strain UW-3/Cx) to induce infe

281 positive for T. vaginalis (P < 0.0002 versus C. trachomatis).

282 d vaginal squamous epithelial cells, whereas C. trachomatis did not.

283 d that CVM was significantly associated with C. trachomatis infection (odds ratio [OR], 4.2 [95% conf

284 Host sphingomyelin was associated with C. trachomatis isolated by detergent extraction, but it

285 Characteristics associating with C. trachomatis infection were examined using bivariable

286 to 18]) and there were no associations with C. trachomatis load or disease severity.

287 with positive cultures) mice challenged with C. trachomatis serovars of the same complex were protect

288 from patients with symptoms consistent with C. trachomatis conjunctivitis and with previously demons

289 By comparison, mice vaginally infected with C. trachomatis exhibited transient low-burden infections

290 ling of human epithelial cells infected with C. trachomatis plasmid-bearing (A2497) and plasmid-defic

291 for tubal infertility in women infected with C. trachomatis.

292 ical assays, we observed that infection with C. trachomatis led to downregulated expression of induci

293 re susceptible to endometrial infection with C. trachomatis, suggesting a role for group 3-like ILCs

294 or protection against genital infection with C. trachomatis.

295 Repeated infections with C. trachomatis lead to serious sequelae, such as inferti

296 ccinated by mucosal and systemic routes with C. trachomatis serovar D (UW-3/Cx) rMOMP and challenged

297 for up to 84 days and (ii) swabs seeded with C. trachomatis and N. gonorrhoeae and then placed in tra

298 Of the 35 subjects with C. trachomatis strains genotyped at enrollment and follo

299 ited symptomatic and asymptomatic women with C. trachomatis (CT) infection and asymptomatic, uninfect

300 red to obtain these electron carriers within C. trachomatis are poorly understood.